Covestor LTD Incyte Corp Transaction History

Covestor LTD

$160 Million
Q3 2024

A detailed history of Covestor LTD transactions in Incyte Corp stock. As of the latest transaction made, Covestor LTD holds 3,993 shares of INCY stock, worth $273,201. This represents 0.17% of its overall portfolio holdings.

Number of Shares

3,993

Previous 4,588 12.97%

Holding current value

$273,201

Previous $278,000 5.04%

% of portfolio

0.17%

Previous 0.18%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$57.33 - $68.61 $34,111 - $40,822	-595 Reduced 12.97%	3,993 $264,000
Q2 2024 Aug 09, 2024	BUY	$51.18 - $63.75 $10,184 - $12,686	199 Added 4.53%	4,588 $278,000
Q1 2024 May 10, 2024	BUY	$56.55 - $66.59 $147,652 - $173,866	2,611 Added 146.85%	4,389 $250,000
Q4 2023 Feb 09, 2024	BUY	$52.16 - $64.19 $8,971 - $11,040	172 Added 10.71%	1,778 $112,000
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $20,739 - $23,668	359 Added 28.79%	1,606 $93,000
Q2 2023 Aug 11, 2023	SELL	$60.95 - $75.51 $66,984 - $82,985	-1,099 Reduced 46.85%	1,247 $78,000
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $47,124 - $57,712	-671 Reduced 22.24%	2,346 $170,000
Q4 2022 Feb 13, 2023	BUY	$67.18 - $84.11 $36,747 - $46,008	547 Added 22.15%	3,017 $242,000
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $95,828 - $119,981	1,448 Added 141.68%	2,470 $165,000
Q2 2022 Aug 10, 2022	SELL	$66.18 - $83.18 $121,175 - $152,302	-1,831 Reduced 64.18%	1,022 $78,000
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $114,082 - $137,738	1,728 Added 153.6%	2,853 $227,000
Q4 2021 Feb 10, 2022	BUY	$63.34 - $74.11 $71,257 - $83,373	1,125 New	1,125 $83,000

Others Institutions Holding INCY

# of Institutions

643

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.2B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account